The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print Cited Medium: Print ISSN: 1351-5101 (Print) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE
    • Publication Information:
      Publication: <2014- > : Oxford : Wiley
      Original Publication: Oxford ; New York : Rapid Communications, [1994-
    • Subject Terms:
      Alleles*; Alzheimer Disease/*drug therapy ; Alzheimer Disease/*genetics ; Apolipoproteins E/*genetics ; Cholinesterase Inhibitors/*therapeutic use ; Tacrine/*therapeutic use; Aged ; Aged, 80 and over ; Alzheimer Disease/psychology ; Apolipoprotein E4 ; Cholinesterase Inhibitors/administration & dosage ; Cognition/drug effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Male ; Psychiatric Status Rating Scales ; Sex Characteristics ; Tacrine/administration & dosage
    • Abstract:
      The objective of our study was to evaluate the effects of the apolipoprotein E (ApoE) phenotype and gender on the response to tacrine treatment in Alzheimer's disease (AD). ApoE phenotyping was performed on 76 patients treated with tacrine for AD. This group comprised 33 ApoE epsilon4 allele carriers (epsilon4+) and 43 non-epsilon4 carriers (epsilon4-). Patients were treated blindly in relation to the ApoE phenotype, with incremental tacrine dosages ranging from 40 mg/day up to the highest dosage (160 mg) tolerated without side-effects. At least 6 weeks elapsed between each increase. Changes in the scores for the Alzheimer Disease Assessment Scale-Cognitive Component (ADAS-Cog) between baseline and each increment in dosage were assessed in the epsilon4- and epsilon4+ groups. The cut-off point for being considered as responsive to tacrine treatment was a 4-point decrease in the ADAS-Cog score. There was no tendency for the epsilon4- carriers to respond better than the epsilon4+ carriers. When patients were stratified by gender, no differences were found between the effects of the treatment on men and women. Consequently, these results do not support the hypothesis that the ApoE phenotype and gender are predictors of the response to tacrine in AD patients.
    • Accession Number:
      0 (Apolipoprotein E4)
      0 (Apolipoproteins E)
      0 (Cholinesterase Inhibitors)
      4VX7YNB537 (Tacrine)
    • Publication Date:
      Date Created: 20000725 Date Completed: 20000823 Latest Revision: 20191104
    • Publication Date:
      20221213
    • Accession Number:
      10.1046/j.1468-1331.2000.00073.x
    • Accession Number:
      10886308